← Back to headlines
Insmed Stock Rises Following Positive Arikayce Lung Infection Trial Results
Insmed's stock has seen a rise after the company announced positive late-stage trial results for its drug Arikayce, which is used to treat lung infections.
23 Mar, 16:04 — 23 Mar, 16:04
Sources
Showing 1 of 1 sources
